Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
SRPT has been in the news recently: Sarepta Therapeutics is not mentioned in the provided information, but it is important to note that the company's performance and stock movements are not directly addressed in the context of the recent market updates. The article discusses the rise in shares of Alaska Air Group and Block, as well as Bank of America's neutral rating on Tesla due to potential challenges.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
